GLP-1 Agonist Supplement Composition for Lean Mass Preservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
GLP-1 receptor agonist therapies for type 2 diabetes and weight management often cause side effects such as loss of lean body mass, gastrointestinal issues, and altered food preferences leading to nutritional deficiencies.
Innovation Solution
A dietary supplement composition containing amino acid sources, dietary fiber, and bioactive agents to alleviate side effects like nausea, bloating, and gastrointestinal discomfort, while providing essential nutrients to support lean body mass and overall health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 receptor agonist therapy is administered, then blood glucose control and weight loss are improved, but lean body mass is lost and gastrointestinal side effects occur
Solution Approach 1:
The patent introduces a dietary supplement composition as an intermediary substance that mitigates the harmful effects of GLP-1 agonist therapy. The supplement contains amino acid sources, dietary fiber, and bioactive agents that act as mediators to preserve lean body mass and alleviate gastrointestinal side effects while allowing the continuation of effective glucose control and weight loss therapy
Solution Approach 2:
The patent modifies the nutritional parameters of the patient by introducing a specifically formulated supplement composition. This composition adjusts amino acid intake, dietary fiber consumption, and bioactive agent supplementation to counteract the catabolic effects of GLP-1 agonists, thereby preserving lean body mass while maintaining weight loss benefits
2Reliability
If GLP-1 receptor agonist therapy is administered, then weight loss is achieved, but gastrointestinal side effects such as nausea and bloating increase
Solution Approach 1:
The supplement composition serves as a protective intermediary that reduces the harmful gastrointestinal effects of GLP-1 agonist therapy. By incorporating bioactive anti-emetic agents, anti-bloating agents, and dietary fiber, the supplement mediates between the weight loss benefits and the gastrointestinal discomfort, allowing patients to maintain weight loss while experiencing reduced nausea, vomiting, bloating, and digestive issues
3Reliability
If GLP-1 receptor agonist therapy is administered, then appetite is regulated, but food preferences alter leading to reduced intake of protein, fiber, and micronutrients
Solution Approach 1:
The dietary supplement acts as an intermediary that compensates for the reduced intake of essential nutrients caused by altered food preferences. The supplement provides amino acid sources to replace reduced protein intake, dietary fiber to compensate for lower fiber consumption, and a comprehensive array of vitamins and minerals to make up for decreased micronutrient intake, thereby maintaining nutritional status while preserving appetite regulation benefits
Data Source
AI summary
A composition for consumption by an individual who is being treated with a GLP-1 agonist, including: at least one amino acid source in an amount effective to alleviate loss of lean body mass as a side effect of being treated with the GLP-1 agonist; at least one dietary fiber; and a therapeutically effective amount of at least one of a bioactive anti-emetic agent, an anti-bloating agent, an anti-diarrheal agent and an anti-constipation agent, wherein the composition is a premix or a ready-to-drink supplement effective to alleviate at least one additional side effect of being treated with the GLP-1 agonist, which is selected from nausea, bloating, vomiting, diarrhea and constipation. A method for alleviating loss of lean body mass and at least one additional side effect of being administered a GLP-1 agonist, includes feeding the composition to an individual who is being administered the GLP-1 agonist.